Cue Biopharma (CUE) Change in Account Payables (2017 - 2025)

Cue Biopharma has disclosed Change in Account Payables across 9 years of filings, most recently posting $1.6 million for Q4 2025.

• Change in Account Payables for Q4 2025 came in at $1.6 million, up 143.86% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.1 million (up 265.93% YoY), and the FY2025 annual result was $1.1 million, up 265.93% from the prior year.
• Change in Account Payables came in at $1.6 million for Q4 2025 at Cue Biopharma, up from -$1.3 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $2.6 million in Q3 2024 to a low of -$3.6 million in Q4 2024.
• The 5-year median for Change in Account Payables is $163500.0 (2021), against an average of $91019.9.
• Across the five-year window, Change in Account Payables slumped 2330.77% in 2023 and surged 1970.16% in 2024, its largest moves.
• Cue Biopharma's Change in Account Payables stood at $120398.0 in 2021, then surged by 422.43% to $629000.0 in 2022, then surged by 62.32% to $1.0 million in 2023, then tumbled by 457.49% to -$3.6 million in 2024, then surged by 143.86% to $1.6 million in 2025.
• The last three Change in Account Payables figures came in at $1.6 million (Q4 2025), -$1.3 million (Q3 2025), and -$157000.0 (Q2 2025), per Business Quant data.